SSKN Strata Skin Sciences

STRATA Skin Sciences Names John Bagdasarian as Vice President of Professional Relations

STRATA Skin Sciences Names John Bagdasarian as Vice President of Professional Relations

Announces Participation in the 2022 American Academy of Dermatology Meeting

HORSHAM, Pa., March 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that John Bagdasarian has joined the company as Vice President of Professional Relations.

In this newly created position, Mr. Bagdasarian will be responsible for establishing STRATA’s relationships with key advocacy groups focused on dermatology and skin disease. He will also spearhead the Company’s presence at dermatological meetings, build relationships with key opinion leaders and establish STRATA’s first Advisory Committee.  

“We are delighted to welcome John to the STRATA team,” said Bob Moccia, Chief Executive Officer of STRATA. “He brings deep sector experience and an extensive network of industry relationships, further expanding the formidable team built by STRATA over the past year. Moreover, we are confident that John’s past success in creating strong professional relations programs in life sciences will add significant value to our sales and marketing initiatives.”

Mr. Bagdasarian has over 20 years of healthcare sales and professional relations experience. Prior to joining STRATA, he was the senior director of professional relations at Incyte Corporation where he effectively strengthened the company’s corporate position and brand awareness among KOL and constituency groups. Throughout his career, Mr. Bagdasarian has executed numerous professional relations strategies for both private and publicly traded companies; including EPI Health, Inc, Alcaris Therapeutics, Valeant Pharmaceuticals, Graceway Pharmaceuticals and 3M Pharmaceuticals. Mr. Bagdasarian holds a B.S. degree in Business Administration, with a concentration in Financial Management, from State University of New York at Brockport.

“I am thrilled to join one of the most innovative companies in dermatology,” said Mr. Bagdasarian. “I look forward to collaborating with the team to accelerate STRATA’s growth and achieve more awareness among leaders in the broader dermatology and medical device spaces.”

American Academy of Dermatology

STRATA Skin Sciences will be participating in the upcoming Annual American Academy of Dermatology Meeting on March 25th – 29th in Boston, Massachusetts, including a reception on Friday evening. Contact Keith Simeone, VP Sales () for further information.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the in-office treatment of dermatologic conditions. Its products include the XTRAC®, XTRAC Momentum™ 1.0 and Pharos® excimer lasers, VTRAC® lamp systems, and TheraClear treatment system utilized in the treatment of psoriasis, vitiligo, acne and various other skin conditions.

The Company’s proprietary XTRAC, XTRAC Momentum™ 1.0 and recently acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents. Additionally, STRATA’s recently acquired assets related to Theravant Corporation’s TheraClear system allows the company the expand into the U.S. acne care market.

STRATA’s unique business model in the U.S. leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

Investor Contact

Jack Droogan

(203) 585-4140

 



EN
14/03/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Strata Skin Sciences

 PRESS RELEASE

STRATA Skin Sciences Confirms Nasdaq Delisting

STRATA Skin Sciences Confirms Nasdaq Delisting HORSHAM, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that a Form 25 has been filed today with the SEC to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and confirms that trading of the Company’s common stock has been suspended from trading on The Nasd...

 PRESS RELEASE

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and A...

Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser Latest STRATA customer strengthens academic leadership in XTRAC excimer laser treatment for psoriasis, vitiligo, and atopic dermatitis HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatme...

 PRESS RELEASE

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Effi...

STRATA Skin Sciences Highlights Meta-Analysis Confirming Clinical Efficacy of 308 nm Excimer Laser for Plaque Psoriasis Growing body of clinical data like February 2026 publication from Georgetown University supports optimized, targeted Excimer laser UVB strategies for inflammatory skin conditions HORSHAM, Pa., Feb. 17, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today highlights findings from a February 2026 systematic review and meta-analysis...

 PRESS RELEASE

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 20...

STRATA Skin Sciences Showcases XTRAC® and TheraclearX® at TeraCILAD 2025 — Reports Early Adoption Momentum in Mexico HORSHAM, Pa., Dec. 09, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a global leader in in-office dermatologic technologies, announces its participation in the 2025 Ibero-Latin American Congress of Dermatology (TeraCILAD) November 19-22, 2025, where it presented its XTRAC® excimer laser and TheraclearX® acne therapy system. STRATA also reported that, by the end of 2025, there will be over 12 new recurring TheraclearX® accounts in Mexico, reflecting gro...

Strata Skin Sciences Inc: 1 director

A director at Strata Skin Sciences Inc sold/bought 19,094 shares at 1.334USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last tw...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch